Pakistan Stock Exchange (PSX) · Pakistan · Updated after 27 Oct 2026 close
BF Biosciences
BFBIO · Pakistan Stock Exchange (PSX) · prices in PKR
PKR 123.20▲ +0.20 (0.16%)
About BF Biosciences
BF Biosciences Limited is a pharmaceutical company whose core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products. It operates within the pharmaceutical industry as a joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. Pharmaceutical products are medicines and related preparations made for treating and preventing illness, and bringing them to market typically spans importing, manufacturing, promotion and distribution to those who prescribe and use them.
The shares are listed on the Pakistan Stock Exchange (PSX) under the code BFBIO, and the price on this page is in Pakistani rupees (PKR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Fair price profile
Ranks #230 of 542 on the Pakistan Stock Exchange (PSX) · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Pakistan yet.
TrendWeak
37/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-11.6%
From 52-week high-28.5%
MomentumWeak
39/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-6.1%
6-month return-15.8%
12-month, skipping last month-17.4%
Stability (higher is calmer)Strong
76/100
Calmer than most: low volatility and shallow drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)35.5%
Worst drawdown, 1 year (smaller is calmer)-30.3%
LiquidityStrong
75/100
Trades actively.
See the numbers →
Avg daily value traded25.18M PKR
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Pakistan when fundamentals data for this market is added. All Pakistan stocks.
Latest results
Announced 28 Oct 2026 · Quarter ended 30 Sep 2026Earnings per share
PKR 2.09
a year earlier: 1.81 (+15%)
Profit after tax
PKR 185 mn
a year earlier: PKR 160 mn (+16%)
Figures are read from the company's results announcement to the Pakistan Stock Exchange and checked against the exchange's own table for the same period a year earlier. The exchange's own statement table is updated later; the trailing P/E and fair value on this page already include this period.
Fair value estimate · limited data
PKR 148.46range of models 142.44 – 151.88
Undervalued
+20.5% to fair value
Average of the 3 valuation models that pass our checks. Undervalued or Overvalued means the gap to fair value is more than 17.5%. Model uncertainty is High.
PSX income statement only (no balance sheet or cash flow): only earnings and sales models can be built. Their weights were fitted to a professional consensus-style valuation of Pakistani stocks and checked on stocks that were not used for the fit, but they use no analyst forecasts. Treat this as a rough estimate.
P/E multiple
PKR 151.06
P/S multiple
PKR 151.88
P/E on average earnings
PKR 142.44
Each model multiplies the company's trailing-twelve-month earnings (or sales) by a multiple that blends its own current multiple, its own history and its sector median. Earnings per share by fiscal year, newest first: 7.16, 5.52. Source: statements and price from the Pakistan Stock Exchange portal and end-of-day data. A model estimate, not a price target or advice. How it works.
Factor ratings for BFBIO
Each factor is rated by where BFBIO stands among the 14 stocks of its PSX sector (Pharmaceuticals; all PSX stocks when the sector is too small for a fair comparison).
Rating against the group
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
For valuation factors Good means cheaper than most of the group, which is not the same as a bargain.
In total: 3 Good · 7 Average · 0 Bad of 10
Growth: 1 · 1 · 0
Profitability: 0 · 1 · 0
Valuation: 0 · 2 · 0
Price risk and momentum: 1 · 2 · 0
Liquidity: 1 · 1 · 0
| Factor | BFBIO | Rating | Group median |
|---|---|---|---|
| Growth | |||
| Sales growth, last financial year | +62.1% | Good beats 96% | +11.0% |
| Profit growth, last financial year | +41.4% | Average beats 58% | +39.2% |
| Profitability | |||
| Net profit margin | 6.7% | Average beats 39% | 10.0% |
| Valuation | |||
| P/E ratio (last 12 months) | 16.7x | Average beats 35% | 11.7x |
| Price / sales | 1.2x | Average beats 61% | 1.2x |
| Price risk and momentum | |||
| Volatility, 1 year | 35.5% | Average beats 54% | 36.4% |
| Worst drawdown, 1 year | −30.3% | Good beats 89% | −35.3% |
| 12-month return, skipping the last month | −17.4% | Average beats 54% | −17.6% |
| Liquidity | |||
| Average daily value traded | PKR 25.2M | Good beats 68% | PKR 15.8M |
| Days with no trading | 0.0% | Average beats 50% | 0.0% |
Built from the income-statement summary the Pakistan Stock Exchange publishes (sales, profit and EPS for up to four financial years, trailing P/E, market value) and our own end-of-day prices. The PSX portal has no balance sheet or cash flow, so there are no debt, cash-flow or book-value factors. A factor is left out when its data is missing or meaningless (for example a P/E on a loss). These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the Market X-Ray.
Price chart
52-wk range 117.20 – 177.99 Daily closes, split-adjusted
Signals
50-day average127.36
200-day average139.42
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)3.93
Technical summary
Daily
Strongly bearish
2 bullish · 2 neutral · 12 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 9 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 4 bearish
Moving averages (daily)
| SMA 10 | 125.7 | Bearish |
| EMA 10 | 124.7 | Bearish |
| SMA 20 | 125.3 | Bearish |
| EMA 20 | 125.3 | Bearish |
| SMA 50 | 127.4 | Bearish |
| EMA 50 | 127.3 | Bearish |
| SMA 100 | 132.0 | Bearish |
| EMA 100 | 131.1 | Bearish |
| SMA 200 | 139.4 | Bearish |
| EMA 200 | 137.3 | Bearish |
Oscillators (daily)
| RSI (14) | 42.40 | Neutral |
| MACD (12, 26) | -0.77 | Bearish |
| Momentum (12) | -0.79 | Bearish |
| Stochastic %K (14) | 11.92 | Bullish |
| Williams %R (14) | -88.08 | Bullish |
| CCI (20) | -67.46 | Neutral |
Pivot points (classic, last session)
S3 120.7 | S2 121.9 | S1 122.5 | Pivot 123.7 | R1 124.3 | R2 125.5 | R3 126.1 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in PKR. Educational only, not financial advice.